{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:02:17Z","timestamp":1791666137016,"version":"4.3.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>CD20 monoclonal antibodies (mAbs), particularly rituximab, have become a preferred treatment for many patients with phospholipase A2 receptor (PLA2R)-related membranous nephropathy (MN). However, some patients either fail to respond to rituximab or experience adverse reactions, indicating that newer-generation CD20 mAbs may offer a more effective alternative. Recently, subcutaneous ofatumumab has been utilized in the treatment of relapsing multiple sclerosis (RMS). This study presents two patients of primary membranous nephropathy (PMN) patients who were treated with subcutaneous ofatumumab. One patient was unresponsive to immunosuppressive therapies, while the other experienced recurrence after drug withdrawal. After ofatumumab therapy, Case 1 achieved PLA2R antibody negativity, and Case 2 showed improvements in renal function and hypoproteinemia. Both cases experienced a reduction in proteinuria. No adverse reactions were reported during the observation period. In conclusion, this study highlights the efficacy and safety of subcutaneous ofatumumab in treating PMN, particularly in patients who have failed or relapsed after conventional therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1610530","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T07:45:04Z","timestamp":1751269504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-Ru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.10.009","article-title":"Membranous nephropathy: core curriculum 2021","volume":"77","author":"Alsharhan","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040513","article-title":"Mechanisms of primary membranous nephropathy","volume":"11","author":"Gu","year":"2021","journal-title":"Biomolecules"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/postgradmedj-2018-135729","article-title":"Primary membranous nephropathy: comprehensive review and historical perspective","volume":"95","author":"Keri","year":"2019","journal-title":"Postgrad Med J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00467-019-04425-1","article-title":"Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era","volume":"36","author":"Safar-Boueri","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2104-177","article-title":"Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis","volume":"51","author":"You","year":"2021","journal-title":"Turk J Med Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.33314\/jnhrc.v18i4.2481","article-title":"The efficacy of rituximab in the treatment of membranous nephropathy","volume":"18","author":"Maharjan","year":"2021","journal-title":"J Nepal Health Res Counc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab316","article-title":"The management of membranous nephropathy\u2014an update","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01855-y","article-title":"Update on the application of monoclonal antibody therapy in primary membranous nephropathy","volume":"83","author":"Deng","year":"2023","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121118","article-title":"Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I\/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"40","author":"Kurrasch","year":"2013","journal-title":"J Rheumatol"},{"key":"B13","unstructured":"Ofatumumab\n          \n          \n          Bethesda (MD\n          NIDDK\n          LiverTox: clinical and research information on drug-induced liver injury\n          \n          2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40265-021-01650-7","article-title":"Ofatumumab: a review in relapsing forms of multiple sclerosis","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S303279","article-title":"Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review","volume":"15","author":"Overton","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: a systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: a systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae129","article-title":"Ten tips on immunosuppression in primary membranous nephropathy","volume":"17","author":"Trujillo","year":"2024","journal-title":"Clin Kidney J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult Scler"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult Scler"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108635","article-title":"Novel treatment options in rituximab-resistant membranous nephropathy patients","volume":"107","author":"Ahmadian","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.04.009","article-title":"Structure of the Fab fragment of therapeutic antibody ofatumumab provides insights into the recognition mechanism with CD20","volume":"46","author":"Du","year":"2009","journal-title":"Mol Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1517\/14712590903586239","article-title":"Ofatumumab: a novel monoclonal anti-CD20 antibody","volume":"10","author":"Osterborg","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness","volume":"13","author":"Podest\u00e0","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-019-09872-z","article-title":"Low-dose subcutaneous anti-CD20 treatment depletes disease-relevant B cell subsets and attenuates neuroinflammation","volume":"14","author":"Huck","year":"2019","journal-title":"J Neuroimmune Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12882-023-03206-1","article-title":"Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/archopthalmol.2011.1215","article-title":"Small dose of rituximab for Graves orbitopathy: new insights into the mechanism of action","volume":"130","author":"Salvi","year":"2012","journal-title":"Arch Ophthalmol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610530\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T07:45:09Z","timestamp":1751269509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1610530\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2025.1610530"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1610530","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1610530"}}